No OS benefit with tasquinimod in mCRPC
The oral immunotherapy tasquinimod improved radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC), but the drug failed to improve overall...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Cancer | Cancer & Oncology | Family Practices | Immunotherapy | Oral Cancer | Primary Care | Prostate Cancer | Radiography